ScripMega-sized financing deals backed by venture capital and private equity firms have bypassed Chinese biotechs, since a string of transactions worth $100m impressed the sector around the turn of the yea
ScripShanghai-based Everest Medicines Limited has become the latest Chinese biotech to leap into the mRNA fray through an in-licensing deal with the Canadian biotech Providence Therapeutics Holdings Inc
ScripScrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. GC Pharma, Speragen To Co-Develop SSADH
ScripShanghai-based immuno-oncology developer Shanghai Junshi Biosciences Co., Ltd. has pledged up to RMB799m ($123m) in a joint venture with Immorna , a domestic messenger RNA technology specialist. Th